10-K: Veru Inc. Reports Fiscal Year 2024 Results, Focuses on Enobosarm Development

Veru Inc. reports a net loss for fiscal year 2024 while advancing its enobosarm program for obesity and seeking external funding for sabizabulin.

Summary

• Veru Inc. reported a net loss of $37.8 million for fiscal year 2024, compared to a net loss of $93.2 million in fiscal 2023.
• Net revenues increased by 4% year-over-year to $16.9 million, primarily from sales of FC2.
• The company is prioritizing the development of enobosarm for obesity, with a Phase 2b clinical trial underway and topline results expected in January 2025.
• Development of enobosarm for breast cancer and sabizabulin for ARDS is contingent on securing additional funding.
• The company is also focused on growing its FC2 business through its own telehealth portal and global public health sector partnerships.
• The company has a significant amount of net operating loss carryforwards, but a valuation allowance has been recorded against these assets.
• The company is not eligible to use its current effective shelf registration statement on Form S-3 or file new registration statements on Form S-3 until March 1, 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in the enobosarm program and a reduction in net loss, the company faces significant financial challenges, including the need for additional funding and the loss of a major customer. The reliance on external funding for key programs and the ineligibility to use its shelf registration statement until March 1, 2025, create uncertainty and a negative outlook.

Positives

• The company's net loss decreased significantly from $93.2 million in fiscal 2023 to $37.8 million in fiscal 2024.
• Net revenues increased by 4% year-over-year.
• The Phase 2b clinical trial for enobosarm in obesity is fully enrolled and on track for topline results in January 2025.
• The company is developing a novel modified release formulation for enobosarm.
• The company has a strong focus on growing its FC2 business through its own telehealth portal and global public health sector partnerships.

Negatives

• The company reported a net loss of $37.8 million for fiscal year 2024.
• The company's FC2 business has seen decreasing sales due to lower volume from digital telemedicine customers.
• The company is not eligible to use its current effective shelf registration statement on Form S-3 or file new registration statements on Form S-3 until March 1, 2025.
• The company has a $3.9 million allowance for credit losses related to The Pill Club bankruptcy.
• The company is subject to significant payment obligations pursuant to the resolution of a dispute with a supplier.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding.
• The company's clinical trials may be delayed, suspended, or terminated.
• The company may not be able to obtain regulatory approval for its drug candidates.
• The company may not be able to successfully commercialize its drug candidates.
• The company faces competition from other pharmaceutical companies.
• The company relies on third-party manufacturers and suppliers.
• The company is subject to government contracting risks.
• The company is subject to cybersecurity risks and data security incidents.
• The company may not receive any additional payments from ONCO in connection with the sale of its ENTADFI assets.

Future Outlook

The company plans to prioritize the development of enobosarm for obesity and seek external funding for sabizabulin for ARDS. The company expects topline results from the Phase 2b clinical trial for enobosarm in obesity in January 2025 and from the Phase 2b extension clinical study in the second quarter of calendar 2025. The company also anticipates a Phase 1 bioavailability clinical trial for a novel modified release formulation of enobosarm during the first half of 2025.

Management Comments

• The company is focused on the clinical development and commercialization of novel medicines for the treatment of metabolic diseases, oncology, and ARDS.
• The company is prioritizing the use of its internal cash and the net proceeds of any future financings for the development of enobosarm.
• The company is seeking external funding through government grants, pharmaceutical company partnerships, or similar sources to advance the development of sabizabulin as a treatment for viral-induced ARDS.
• The company remains focused on increasing revenue from FC2 in the U.S. market via its established dedicated direct to patient telemedicine and pharmacy services portal.

Industry Context

The company is operating in a competitive pharmaceutical industry, particularly in the areas of obesity, breast cancer, and infectious diseases. The company is also navigating the evolving landscape of telehealth and the global public health sector.

Comparison to Industry Standards

• The company's focus on enobosarm for obesity aligns with the growing market for weight loss drugs, particularly GLP-1 receptor agonists, and the need to address muscle loss associated with these treatments. Competitors in this space include major pharmaceutical companies developing similar or competing therapies.
• The company's development of enobosarm for breast cancer targets a significant unmet need in hormone receptor-positive metastatic breast cancer, where resistance to existing therapies is common. Competitors in this space include companies developing novel endocrine therapies and CDK4/6 inhibitors.
• The company's development of sabizabulin for ARDS addresses a critical need for effective treatments for viral-induced respiratory distress. Competitors in this space include companies developing antiviral and anti-inflammatory therapies.
• The company's FC2 product competes with male condoms and other female condoms in the global market. Competitors in this space include companies with greater financial resources and established brands.

Legal Proceedings

• The company is a defendant in a securities class action lawsuit and several derivative lawsuits related to statements about sabizabulin as a treatment for COVID-19.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential losses due to the company's need for additional capital.
• Employees may be affected by potential cost-cutting measures or changes in the company's strategic direction.
• Customers of FC2 may experience changes in access or pricing due to the company's evolving distribution strategies.
• Suppliers may be affected by the company's financial challenges and potential changes in its supply chain.

Next Steps

• The company will continue to enroll patients in the Phase 2b extension clinical trial for enobosarm in obesity, with topline results expected in the second quarter of calendar 2025.
• The company will seek external funding for the development of sabizabulin for viral-induced ARDS.
• The company will continue to grow its FC2 business through its own telehealth portal and global public health sector partnerships.
• The company will continue to develop a novel modified release formulation for enobosarm, with Phase 1 bioavailability trials anticipated in the first half of 2025.

Key Dates

Keywords

enobosarm, sabizabulin, FC2, obesity, breast cancer, ARDS, clinical trials, telehealth, pharmaceutical, biopharmaceutical, sexual health, metabolic diseases, oncology, FDA, GLP-1 RA